Eversept Partners LP Has $14.95 Million Stock Position in Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Eversept Partners LP increased its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 12.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 779,998 shares of the company's stock after acquiring an additional 88,766 shares during the period. Viridian Therapeutics makes up about 1.3% of Eversept Partners LP's investment portfolio, making the stock its 15th largest position. Eversept Partners LP owned approximately 0.98% of Viridian Therapeutics worth $14,953,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of VRDN. R Squared Ltd bought a new stake in shares of Viridian Therapeutics in the 4th quarter worth approximately $26,000. AlphaQuest LLC increased its holdings in shares of Viridian Therapeutics by 119.0% in the fourth quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after buying an additional 1,519 shares in the last quarter. Summit Investment Advisors Inc. increased its holdings in shares of Viridian Therapeutics by 24.7% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after buying an additional 1,516 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of Viridian Therapeutics during the 4th quarter valued at $164,000. Finally, KLP Kapitalforvaltning AS bought a new stake in shares of Viridian Therapeutics during the 4th quarter worth $219,000.

Viridian Therapeutics Stock Down 0.4 %

VRDN traded down $0.06 on Friday, reaching $13.50. 524,676 shares of the company traded hands, compared to its average volume of 1,203,124. The company has a market cap of $1.10 billion, a price-to-earnings ratio of -3.13 and a beta of 0.81. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The stock's 50 day moving average price is $14.24 and its 200-day moving average price is $18.24. Viridian Therapeutics, Inc. has a 52-week low of $9.90 and a 52-week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($1.05) by $0.24. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The business had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.05 million. On average, sell-side analysts expect that Viridian Therapeutics, Inc. will post -4.03 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

VRDN has been the subject of several analyst reports. Needham & Company LLC reaffirmed a "buy" rating and set a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. HC Wainwright reaffirmed a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a research note on Wednesday. Three research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.